HRT Not Working? What to Do Next — Before You Change Anything

The honest part, up front

In a Cochrane meta-analysis of 24 randomized controlled trials covering 3,329 women, oral estrogen or oral estrogen-plus-progestogen reduced hot flash frequency by a pooled average of about 75% compared with placebo. That is a group-level average from trials of oral therapy. It is not an individual success threshold, not a ceiling on the benefit any one person can get, and not a reason to accept symptoms you find unacceptable.

Start here because it’s free, it takes five minutes, and it changes how you read every other check. The Cochrane review pooled 24 randomized trials and 3,329 women. Averaged across all of them, hot flash frequency fell by roughly 75% compared with placebo.

Do your own arithmetic:

Some menopause symptoms may begin improving within weeks of starting hormone therapy, and around three months is a common point to review efficacy and tolerability. Sleep, mood, cognitive, vaginal, and urinary symptoms may follow different patterns from hot flashes and may have independent causes. Symptoms that are worsening, significant side effects, unexpected bleeding, or an inability to use the product correctly are reasons to make contact sooner.

Most pages give you one timeline. That’s the error, because your symptoms don’t share a clock.

There’s a chain in that middle column: night sweats → sleep → mood and fog. If your hot flashes are much better but you still feel foggy at six weeks, you may be watching that chain resolve from the bottom up. Or the fog may be its own thing. Both are common, and the way you tell them apart is whether the sleep improved first.

Estradiol transdermal patches have been listed on the American Society of Health-System Pharmacists (ASHP) drug shortage bulletin since January 30, 2026, with the bulletin updated on July 1, 2026. Affected manufacturers have varied over the course of the disruption and have included both once-weekly and twice-weekly products. Because availability changes by product, strength, package, pharmacy, and date, a patient may receive a different manufacturer’s product at the same labeled delivery rate. Comparing the manufacturer and wear schedule on the last two prescription labels is a free check.

This one’s new. It didn’t apply in 2024 and it may not apply next year.

What happened

On November 10, 2025, the FDA initiated class-wide labeling changes for menopausal hormone therapy, moving to remove boxed warnings about cardiovascular disease, breast cancer, and dementia that had sat on those labels since 2003. On February 12, 2026, updated labeling was approved for an initial six products. Demand moved fast. By January 30, 2026, ASHP had opened a shortage bulletin on estradiol transdermal systems. It’s still open, and it was updated on July 1, 2026.

What that means at your pharmacy

Manufacturers have moved on and off the affected list as the disruption has run — Amneal, Noven, Zydus, and Sandoz have all appeared. Both once-weekly and twice-weekly products have been affected. Availability varies by product, strength, package size, pharmacy, and week.

Which is why we’re not printing a status table here. Any table we published would be wrong by the time you read it, and a wrong table is worse than none. ASHP’s bulletin is the live source, and your pharmacist has the version that matters — what’s actually on their shelf today.

Why this can look like “my HRT stopped working”

Your prescription says estradiol 0.05 mg/24hr. It doesn’t name a manufacturer. So when your pharmacy can’t get one, they fill it with another separately FDA-approved estradiol transdermal product at the same labeled delivery rate — often without a phone call. Those products aren’t identical. They can differ in adhesive, dimensions, wear schedule, and instructions. If your body was managing on one and you were switched to another, the timing can look exactly like your HRT randomly quitting.

What to ask for

1. Ask your pharmacist:“Which manufacturer did you fill this with? Has it changed? Can you order the one I was on before, or does another pharmacy nearby stock it?”
2. Ask your prescriber about a different route, not a different dose. Gels, sprays, and pills are FDA-approved and aren’t affected by patch supply.
3. Ask whether a longer fill is possible— that depends on your prescription, your insurer, state rules, and current supply.
4. Don’t cut, ration, stretch, or re-wear patchesto make a short supply last. It makes your delivery unpredictable in exactly the way that creates the problem you’re trying to solve.

Systemic estrogen therapy can improve vulvar and vaginal symptoms, but genitourinary syndrome of menopause (GSM) may persist during systemic treatment. The 2025 AUA/SUFU/AUGS guideline states that in patients with GSM who are on systemic estrogen therapy, clinicians should offer the option of local low-dose vaginal estrogen or vaginal DHEA. Unlike hot flashes, which typically improve with time, GSM usually worsens over time without treatment.

Here’s the confusing version of “my HRT isn’t working”: your hot flashes improved. Your sleep improved. And you’re still dry, still sore, still dreading sex, still running to the bathroom. So you conclude the HRT is half-failing and ask for more. More systemic estrogen is often not the move.

Genitourinary syndrome of menopause (GSM)is the current term for what used to be called vaginal atrophy. It covers vaginal dryness, burning, itching, pain with sex, urinary urgency, painful urination, and repeat UTIs — all traced to the tissue of the vulva, vagina, and lower urinary tract losing estrogen.

FDA-approved prescription options used for GSM

Three different classes of medicine — they work differently, they’re regulated differently, and they’re not interchangeable.

On recurrent UTIs: the 2025 guideline gives a Grade B recommendation for local low-dose vaginal estrogen to reduce the risk of future UTIs in appropriate postmenopausal patients. If you’re on your third UTI of the year and nobody has raised vaginal estrogen, raise it.

Systemic exposure to transdermal estradiol varies substantially between individuals and is influenced by application site, skin condition, adherence, and product-specific instructions. Adding an extra patch, cutting a patch, or doubling a gel application changes delivery unpredictably and is not a substitute for clinical review.

Systemic HRT only works if the hormone crosses your skin. Poor adhesion makes delivery less reliable — and unreliable delivery makes every other answer on this page harder to trust.

The patch checklist

Go through it honestly. Nobody’s watching.

• Do you know whether yours is once-weekly or twice-weekly? (More people get this wrong than you'd think — especially now, with products being substituted that don't share a schedule.)
• Are you changing it on the right days, consistently?
• Are the edges lifting before it's due to come off?
• Has it ever come off in the shower, in bed, at the gym?
• Are you applying it where your product's label says to? (This varies by brand — yours has a specific answer.)
• Any lotion, oil, sunscreen, or powder on that skin?
• Is the skin under it red, itchy, or irritated?
• Are you rotating sites?
• Does clothing rub it — a waistband, a bra strap?

For gels and sprays

These products are not interchangeable. Divigel isn’t EstroGel isn’t Elestrin isn’t Evamist — different sites, different drying times, different rules about washing and skin contact with other people.

• • Read the instructions for your exact product — the paper in the box
• • Log pumps or sprays, time, and site for two weeks
• • Ask your pharmacist about your specific product: drying time, washing, skin-to-skin contact, missed doses

When hormone therapy is effective and symptoms later return, the chronology is useful information. An abrupt return close to a refill or product change points toward checking the product first. A gradual return over months points toward checking what else has changed. Tachyphylaxis has been described in menopause practice, but symptoms alone cannot establish it and no universal laboratory threshold confirms it.

This is a different problem from “it never worked,” and it deserves a different method. Some clinicians do describe tachyphylaxis — a reduced response over time. So we’re not going to tell you it’s impossible. But you can’t diagnose it from symptoms, no lab threshold confirms it, and it’s a dead-end explanation to reach for first.

First: was it a cliff or a slope?

Pull up your pharmacy history— most chains show it in the app — and write down every refill date for the last twelve months. Now write down when your symptoms came back. If those cluster together, you have a temporal association worth discussing. That’s not proof of anything. It’s ten minutes of work that turns a vague complaint into a specific question, and specific questions get answered.

The change audit

New symptoms that begin after starting or changing hormone therapy are a different clinical question from the original symptoms failing to improve. Headache, breast tenderness, nausea, mood change, and skin reactions are recognized adverse effects of estradiol products. New or worsening symptoms after a treatment change warrant contacting the prescriber rather than waiting for a scheduled review.

Everything above assumes your original symptoms are hanging around. This is the other version: something newshowed up, and it arrived with the treatment. Those are not the same problem and they don’t have the same answer.

Oral hormone therapy has a different troubleshooting pathway from transdermal products. Adherence and timing, medication interactions, and product changes are relevant, while patch-specific issues such as adhesion and application site are not. Serum estradiol is particularly difficult to interpret in patients taking oral estradiol and should not be treated as a direct measure of individual dose adequacy.

Much of the internet’s HRT troubleshooting advice — including a fair chunk of this page — is patch-shaped. If you take a pill, here’s your version.

What’s specific to oral HRT users

• •Adherence and timing. Missed doses matter more than people admit. Take it at the same time daily and note any gaps for two weeks before your review.
• •Missed-dose instructions are product-specific. Ask your pharmacist what to do for your exact product rather than doubling up.
• •Interactions.Some medications affect how oral estrogen is processed. Bring your full list — including supplements — to your review.
• •Blood levels are especially hard to read. Serum estradiol is particularly difficult to interpret with oral estradiol, and it isn’t a direct measure of whether your dose is right for you.

The route question itself is a legitimate thing to raise. If the pill isn’t working for you, “should we look at a different route?” is often a better question than “should we go up a dose?”

Women with a uterus who use systemic estrogen generally require a progestogen to protect the uterine lining. The FDA’s November 10, 2025 labeling initiative did not seek removal of the boxed warning for endometrial cancer from systemic estrogen-alone products. Stopping or skipping a prescribed progestogen without clinical direction removes that protection.

This check is last because acting on it wrongly carries the most risk on this page. If you have a uterus and you’re on systemic estrogen, you’re almost certainly also on a progestogen— micronized progesterone, a synthetic progestin, or a hormonal IUD. It isn’t there for your symptoms. It’s there to protect the lining of your uterus.

Here’s why it belongs on a page about HRT not working: for some women, the progestogen is the part causing trouble. Low mood, bloating, breast tenderness, sleepiness, feeling flat. And because it all started at once, the whole regimen gets labelled “not working” — when the estrogen may be doing fine.

What to do instead

Your progestogen isn’t one thing, and swapping is a normal clinical move:

• • Type — different progestogens have different pharmacologic and adverse-effect profiles
• • Timing — micronized progesterone is often taken at bedtime because it may cause drowsiness; follow your product label
• • Schedule — continuous versus cyclical changes both side effects and bleeding pattern
• • Route — a levonorgestrel IUD delivers progestogen mainly within the uterus and may reduce systemic exposure

On bleeding

Bleeding is common in the first six months of systemic HRT and in the first three months after a dose or product change. What’s expected depends on your regimen. Any postmenopausal or otherwise unexplained bleeding: report it promptly for evaluation. Heavy bleeding, bleeding that won’t stop, or bleeding with faintness, weakness, or severe pain: urgent or emergency care. It’s usually nothing. It gets checked anyway, every time, because of the small number of times it isn’t.

Could something else be causing this? Four look-alikes worth asking about

Several conditions produce symptoms that overlap with menopause, including thyroid dysfunction, iron deficiency, obstructive sleep apnea, and depression. They can coexist with menopause rather than replace it. Evaluation may involve history, symptom screening, laboratory testing, or sleep testing depending on the condition. This list is not exhaustive.

Is my HRT dose too low?

Persistent vasomotor symptoms after an adequate trial can support a clinical review of dose, route, or formulation. Symptoms alone cannot establish that an estrogen dose is insufficient, because timing, delivery, product changes, symptom–treatment mismatch, adverse effects, and other conditions can produce the same presentation. ACOG and The Menopause Society recommend a symptom-based approach to management rather than titrating hormone therapy against laboratory values.

Here it is. The one you came for. It’s check #8 for a reason you can now see: the checks above it are free, fast, and change the answer. If you’ve worked down to here having done them, then yes — a dose, route, or formulation review is exactly the right thing to ask for.

Do I need a blood test to check my estradiol level?

Routine estradiol testing is not recommended for monitoring menopausal hormone therapy in most women. ACOG and The Menopause Society recommend a symptom-based approach rather than titrating to laboratory values. Estradiol levels fluctuate substantially, and published reference ranges vary widely between sources because they are built for different purposes.

You’ve seen the pitch: get your levels tested, find out if you’re “optimized,” discover your dose is subtherapeutic. It’s compelling. It feels scientific. It feels like what your dismissive GP should have been doing.

We compared four published ranges

The same units, side by side. Built for different purposes — read the table with that in mind.

What US guidelines say

ACOG and The Menopause Society recommend a symptom-basedapproach: treatment is guided by how you feel and what side effects you’re getting, not by a lab value. Routine estradiol, progesterone, and testosterone measurement isn’t required for initial management. FSH is not a reliable measure of HRT absorption or dose adequacy, and commercial saliva and urine panels haven’t been established as tools for optimizing your dose.

What should I bring to an HRT review?

A structured symptom and product record improves the quality of a hormone therapy review. Useful information includes the target symptom with a frequency count, the exact product name and manufacturer, the wear schedule, the start or change date, adherence and application details, recent product or pharmacy changes, new medications, and any adverse effects or bleeding.

Two weeks of tracking. That’s the whole ask. It turns “I still feel terrible” — which gets you a shrug — into a clinical picture, which gets you a plan.

The message you can copy and send today

Most practices have a portal. Most portals have a message box. This one gets read:

That last line matters more than you’d think. It tells your clinician you’re a partner, not a risk — and it changes the tone of the reply you get.

When should I consider a different menopause clinician?

Changing providers does not resolve most causes of hormone therapy non-response, because most of the relevant checks are done by the existing prescriber who already holds the patient’s records and history. A different clinician becomes relevant primarily when the current prescriber will not review the regimen, will not consider assessment beyond a dose change, or does not manage menopause routinely.

When a different clinician is the right call

• • You’ve asked for a review and been told to “just give it more time” — twice
• • You raised other possible contributors and were brushed off
• • You raised vaginal symptoms and got a shrug
• • Your prescriber won’t discuss anything except raising or stopping the dose
• • Your prescriber doesn’t do menopause routinely, and it shows
• • You’ve moved, lost coverage, or lost your clinician

What to compare — for this problem specifically

For your problem, which is diagnostic, these matter more than price:

• • Can they order testing when it’s clinically indicated?
• • Can they move you across FDA-approved routes — patch, pill, gel, vaginal?
• • Is there a live conversation, or a form?
• • Insurance, or cash-pay — and what’s the total, including labs and medication?
• • Your state, and licensure
• • Follow-up — can you get back to the same clinician?
• • Cancellation and refund terms before you commit

Price still matters. It’s just not the thing that answers your question.

What if it still isn’t enough after a proper review?

When symptoms remain inadequately controlled after an adequate trial and a structured review, options include referral to a clinician with menopause expertise, a change of route or formulation, addition of local therapy for genitourinary symptoms, assessment of other contributors, or FDA-approved non-hormonal treatments for vasomotor symptoms. An incomplete response to hormone therapy does not mean no treatment will help.

Some women do everything on this page and still don’t land where they want. That deserves a straight answer, not a motivational one. “HRT didn’t fix everything” is not the same as “nothing will help.” Those get collapsed together constantly, and the collapse is what makes women give up.

Frequently asked questions

Short answers to the most common follow-up questions about HRT not working. Each links to the fuller reasoning on this page.